SAT0601 Incidence of Serious Infections in Patients with Rheumatoid Arthritis and Spondyloarthritis Exposed To a-TNF Therapy. Results from Biobadabrasil Registry
| Autor: | Manoel Barros Bertolo, J. Moraes, Claiton Viegas Brenol, B. Stadler, A. Duarte, J. Miranda, G. Castro, V. Fernandes, Roberto Ranza, R. Toledo, M. Sauma, M. Cecconi, D. Titton, Miguel Ángel Descalzo, Ieda Maria Magalhães Laurindo, Ivânio Alves Pereira, Izaias Pereira da Costa, C. Baaklini, H. Carvalho, Valeria Valim, P. Louzada, Geraldo da Rocha Castelar Pinheiro, J. Maciera, M. Freire, Washington A. Bianchi |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Ankylosing spondylitis business.industry Incidence (epidemiology) Immunology medicine.disease General Biochemistry Genetics and Molecular Biology Rheumatology Surgery Psoriatic arthritis Tnf therapy Rheumatoid arthritis Internal medicine medicine Immunology and Allergy In patient business Adverse effect |
| Zdroj: | Annals of the Rheumatic Diseases. 75:887.2-887 |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | Background The safety profile of biologic drugs might have substantial regional differences. Since 2009, the Brazilian Society of Rheumatology runs BiobadaBrasil, a registry for monitoring of biologic therapies in rheumatic diseases, in collaboration with other Latin America countries (BiobadaAmerica) and with Biobadaser Objectives To report the incidence of serious infectious adverse events (SIAE) in Rheumatoid Arthritis (RA) and Spondyloarthritis (SpA) patients exposed to biologic a-TNF drugs in Brazil Methods BiobadaBrasil counts on thirty two centers, from almost all Brazilian states, that prospectively include patients with active rheumatic diseases who started a biologic drug or a synthetic DMARD as a parallel control group. A constant three level monitory of data quality is maintained (online, by phone and “in situ”). This study focuses on SIAE (for definition: Protocolo 1.1 at https://biobadaser.ser.es/biobadamerica/Brasil/cgi-bin/upload/documentacion.aspx) in RA and SpA (Ankylosing Spondylitis+Psoriatic Arthritis) patients exposed to a-TNFs from January 2009 to June 2015. Time of exposure was set from start of the drug to the date of last administration or censorship. Continuous variables were expressed as mean with standard deviation (SD). SAE incidence rate was calculated per 1000 patient/years with 95%CI Results 1601 subjects with RA (1024) and SpA (577) exposed to a-TNF drugs were included in BiobadaBrasil, 6298 p/y, follow-up 2.9 (2.3) yrs, 65% females, at baseline: age 52 (12.5) yrs, disease duration 8.6 (8) yrs. Controls were 572 (RA 528, SpA 44), 2093 p/y, follow-up 3.6 (2.2) yrs, 90% females, at baseline: age 55 (13) yrs, disease duration 5.3 (7.3) yrs. The incidence rates of SIAE were: a-TNF RA & SpA 35 [30,40] vs controls 15 [10,21], ratio 2.34 [1.6,3.5] p Conclusions In BiobadaBrasil registry, patients exposed to a-TNF drugs had an incidence rate of serious infections 2-fold that of the control group, significantly lower in SpA than in RA. Acknowledgement for data monitoring P Cabral, for contributing to BiobadaBrasil registry, L.Barbosa, W.Chahade, A.Hayata, A.Kakehasi, M.Pinheiro, A.Ranzolin, M.Scheinberg, F.Sztajnbok, I.Silveira Disclosure of Interest None declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|